Cardiovascular risk factors and homocysteine in epilepsy

Epilepsy Research

Volumn 76, Issue 2-3, 2007, Pages 113-123

  Elliott, John O ^a   Jacobson, Mercedes P ^b   Haneef, Zulfi ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular risk factors; Epilepsy; Framingham risk score; Homocysteine

Indexed keywords

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; EPILEPSY; EUROPEAN AMERICAN; FEMALE; FRAMINGHAM RISK SCORE; HISPANIC; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SMOKING;

ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; EPILEPSY; HOMOCYSTEINE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; META-ANALYSIS AS TOPIC; MIDDLE AGED; PREVALENCE; RISK FACTORS; SMOKING;

EID: 34548764279     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2007.07.005     Document Type: Article

References (68)

1. American Heart Association Nutrition Committee. Lichtenstein A.H., Appel L.J., Brands M., Carnethon M., Daniels S., Franch H.A., Franklin B., Kris-Etherton P., Harris W.S., Howard B., Karanja N., Lefevre M., Rudel L., Sacks F., Van Horn L., Winston M., and Wylie-Rosett J. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 114 (2006) 82-96
2. Apeland T., Kristensen O., Strandjord R.E., and Mansoor M.A. Thyroid function during B-vitamin supplementation of patients on antiepileptic drugs. Clin. Biochem. 39 (2006) 282-286
3. Apeland T., Mansoor M.A., Pentieva K., McNulty H., and Strandjord R.E. Fasting and post-methionine loading concentrations of homocysteine, vitamin B2, and vitamin B6 in patients on antiepileptic drugs. Clin. Chem. 49 (2003) 1005-1008
4. Apeland T., Mansoor M.A., and Strandjord R.E. Antiepileptic drugs as independent predictors of plasma total homocysteine levels. Epilepsy Res. 47 (2001) 27-35
5. Apeland T., Mansoor M.A., Strandjord R.E., and Kristensen O. Homocysteine concentrations and methionine loading in patients on antiepileptic drugs. Acta Neurol. Scand. 101 (2000) 217-223
6. Arnett D.K., Jacobs Jr. D.R., Luepker R.V., Blackburn H., Armstrong C., and Claas S.A. Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota heart survey, 1980-1982 to 2000-2002. Circulation 112 (2005) 3884-3891
7. Attilakos A., Papakonstantinou E., Schulpis K., Voudris K., Katsarou E., Mastroyianni S., and Garoufi A. Early effect of sodium valproate and carbamazepine monotherapy on homocysteine metabolism in children with epilepsy. Epilepsy Res. 71 (2006) 229-232
8. Booth G.L., and Wang E.E. Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian task force on preventive health care. CMAJ 163 (2000) 21-29
9. Bramswig S., Sudhop T., Luers C., Bergmann K., and Berthold H.K. Lipoprotein(a) concentration increases during treatment with carbamazepine. Epilepsia 44 (2003) 457-460
10. Bramswig S., Kerksiek A., Sudhop T., Luers C., Von Bergmann K., and Berthold H.K. Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults. Am. J. Physiol. Heart Circ. Physiol. 282 (2002) H704-H716
11. Broedl U.C., Geiss H.C., and Parhofer K.G. Comparison of current guidelines for primary prevention of coronary heart disease: risk assessment and lipid-lowering therapy. J. Gen. Intern. Med. 18 (2003) 190-195
12. Carroll M.D., Lacher D.A., Sorlie P.D., Cleeman J.I., Gordon D.J., Wolz M., Grundy S.M., and Johnson C.L. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 294 (2005) 1773-1781
13. Celentano A., Palmieri V., Panico S., Russo C., Arezzi E., Pezzullo S., Minichiello S., Guillaro B., Brancati C., Piccinocchi G., and Di Minno G. Individuals' cardiovascular risk profile projected by family doctors and individuals' knowledge of cardiovascular risk factors: a challenge for primary prevention. The cardiovascular risk prevention project "help your heart stay young". Ital. Heart J. 6 (2005) 557-564
14. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults-United States, 2004. MMWR Morb. Mortal. Wkly. Rep. 54 (2005) 1121-1124
15. Centers for Disease Control and Prevention (CDC). Prevalence of physical activity, including lifestyle activities among adults-United States, 2000-2001. MMWR Morb. Mortal. Wkly. Rep. 52 (2003) 764-769
16. Daviglus M.L., Lloyd-Jones D.M., and Pirzada A. Preventing cardiovascular disease in the 21st century: therapeutic and preventive implications of current evidence. Am. J. Cardiovasc. Drugs 6 (2006) 87-101
17. Deda G., Caksen H., and Icagasioglu D. Effect of long-term carbamazepine therapy on serum lipids, vitamin B12 and folic acid levels in children. J. Pediatr. Endocrinol. Metab. 16 (2003) 193-196
18. Demircioglu S., Soylu A., and Dirik E. Carbamazepine and valproic acid: effects on the serum lipids and liver functions in children. Pediatr. Neurol. 23 (2000) 142-146
19. Department of Health and Human Services, National Institutes of Health. National Heart, Lung and Blood Institute, 2006. Obesity education initiative.
20. Eiris J., Novo-Rodriguez M.I., Del Rio M., Meseguer P., Del Rio M.C., and Castro-Gago M. The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res. 41 (2000) 1-7
21. Fields L.E., Burt V.L., Cutler J.A., Hughes J., Roccella E.J., and Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 44 (2004) 398-404
22. Fokkema M.R., Gilissen M.F., Van Doormaal J.J., Volmer M., Kema I.P., and Muskiet F.A. Fasting vs. nonfasting plasma homocysteine concentrations for diagnosis of hyperhomocysteinemia. Clin. Chem. 49 (2003) 818-821
23. Gaitatzis A., Carroll K., Majeed A.W., and Sander J. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 45 (2004) 1613-1622
24. Greenlund K.J., Zheng Z.J., Keenan N.L., Giles W.H., Casper M.L., Mensah G.A., and Croft J.B. Trends in self-reported multiple cardiovascular disease risk factors among adults in the United States, 1991-1999. Arch. Intern. Med. 164 (2004) 181-188
25. Haffner S.M. Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. Obesity (Silver Spring) 14 Suppl. 3 (2006) 121S-127S
26. Hamed S.A., and Nabeshima T. The high atherosclerotic risk among epileptics: the atheroprotective role of multivitamins. J. Pharmacol. Sci. 98 (2005) 340-353
27. Hedley A.A., Ogden C.L., Johnson C.L., Carroll M.D., Curtin L.R., and Flegal K.M. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291 (2004) 2847-2850
28. Jallon P., and Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf. 24 (2001) 969-978
29. James G.K., Jones M.W., and Pudek M.R. Homocyst(e)ine levels in patients on phenytoin therapy. Clin. Biochem. 30 (1997) 647-649
30. Joshi A.V., Day D., Lubowski T.J., and Ambegaonkar A. Relationship between obesity and cardiovascular risk factors: findings from a multi-state screening project in the United States. Curr. Med. Res. Opin. 21 (2005) 1755-1761
31. Karabiber H., Sonmezgoz E., Ozerol E., Yakinci C., Otlu B., and Yologlu S. Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid. Brain Dev. 25 (2003) 113-115
32. Kieltyka L., Urbina E.M., Tang R., Bond M.G., Srinivasan S.R., and Berenson G.S. Framingham risk score is related to carotid artery intima-media thickness in both white and black young adults: the Bogalusa heart study. Atherosclerosis 170 (2003) 125-130
33. Kishi T., Fujita N., Eguchi T., and Ueda K. Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy. J. Neurol. Sci. 145 (1997) 109-112
34. Lewis D.P., Van Dyke D.C., Willhite L.A., Stumbo P.J., and Berg M.J. Phenytoin-folic acid interaction. Ann. Pharmacother. 29 (1995) 726-735
35. Lloyd-Jones D.M., Leip E.P., Larson M.G., D'Agostino R.B., Beiser A., Wilson P.W., Wolf P.A., and Levy D. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 113 (2006) 791-798
36. Mahmoudian T., Iranpour R., and Messri N. Serum lipid levels during carbamazepine therapy in epileptic children. Epilepsy Behav. 6 (2005) 257-259
37. Mokdad A.H., Ford E.S., Bowman B.A., Dietz W.H., Vinicor F., Bales V.S., and Marks J.S. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289 (2003) 76-79
38. Monane M., Bohn R.L., Gurwitz J.H., Glynn R.J., Levin R., and Avorn J. Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am. J. Public Health 86 (1996) 1805-1808
39. Nakken K.O. Physical exercise in outpatients with epilepsy. Epilepsia 40 (1999) 643-651
40. Nakken K.O., and Kornstad S. Do males 30-50 years of age with chronic epilepsy and on long-term anticonvulsant medication have lower-than-expected risk of developing coronary heart disease?. Epilepsia 39 (1998) 326-330
41. National Cholesterol Education Program, National Heart, Lung and Blood Institute, 2002. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).
42. National Heart, Lung and Blood Institute, 2002. Framingham heart study: 50 years of success.
43. Nilsson L., Tomson T., Farahmand B.Y., Diwan V., and Persson P.G. Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. Epilepsia 38 (1997) 1062-1068
44. Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., and Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 337 (1997) 230-236
45. Nygard O., Vollset S.E., Refsum H., Stensvold I., Tverdal A., Nordrehaug J.E., Ueland M., and Kvale G. Total plasma homocysteine and cardiovascular risk profile. The Hordaland homocysteine study. JAMA 274 (1995) 1526-1533
46. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., and Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 (2006) 1549-1555
47. Raeder S., Landaas S., Laake K., Lyberg T., and Engedal K. Homocysteine measurements in geriatric patients. Scand. J. Clin. Lab. Invest. 66 (2006) 309-315
48. Refsum H., Ueland P.M., Nygard O., and Vollset S.E. Homocysteine and cardiovascular disease. Annu. Rev. Med. 49 (1998) 31-62
49. Rowan A.J., and Epilepsy Foundation of America. Epilepsy in older adults. common morbidities influence development, treatment strategies, and expected outcomes. Geriatrics 60 (2005) 30-32, 34
50. Sander J.W., and Patsalos P.N. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Res. 13 (1992) 89-92
51. Schwaninger M., Ringleb P., Winter R., Kohl B., Fiehn W., Rieser P.A., and Walter-Sack I. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia 40 (1999) 345-350
52. Selhub J., Jacques P.F., Wilson P.W., Rush D., and Rosenberg I.H. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270 (1993) 2693-2698
53. Sener U., Zorlu Y., Karaguzel O., Ozdamar O., Coker I., and Topbas M. Effects of common anti-epileptic drug monotherapy on serum levels of homocysteine, vitamin B12, folic acid and vitamin B6. Seizure 15 (2006) 79-85
54. Sharabi Y., Grotto I., Huerta M., Eldad A., and Green M.S. Risk factor profile for atherosclerosis among young adults in Israel-results of a large-scale survey from the young adult periodic examinations in Israel (YAPEIS) database. Eur. J. Epidemiol. 17 (2001) 757-764
55. Sharma S., Malarcher A.M., Giles W.H., and Myers G. Racial, ethnic and socioeconomic disparities in the clustering of cardiovascular disease risk factors. Ethn. Dis. 14 (2004) 43-48
56. Sheridan S., Pignone M., and Mulrow C. Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J. Gen. Intern. Med. 18 (2003) 1039-1052
57. Sullivan L.M., Massaro J.M., and D'Agostino R.B.S. Presentation of multivariate data for clinical use: the Framingham study risk score functions. Stat. Med. 23 (2004) 1631-1660
58. Tekgul H., Demir N., and Gokben S. Serum lipid profile in children receiving anti-epileptic drug monotherapy: is it atherogenic?. J. Pediatr. Endocrinol. Metab. 19 (2006) 1151-1155
59. Thirup P., and Ekelund S. Day-to-day, postprandial, and orthostatic variation of total plasma homocysteine. Clin. Chem. 45 (1999) 1280-1283
60. Tonstad S., and Hjermann I. A high risk score for coronary heart disease is associated with the metabolic syndrome in 40-year-old men and women. J. Cardiovasc. Risk 10 (2003) 129-135
61. Trocho C., Escola-Gil J.C., Ribas V., Benitez S., Martin-Campos J.M., Rotllan N., Osaba L., Ordonez-Llanos J., Gonzalez-Sastre F., and Blanco-Vaca F. Phenytoin treatment reduces atherosclerosis in mice through mechanisms independent of plasma HDL-cholesterol concentration. Atherosclerosis 174 (2004) 275-285
62. Ueland P.M., Refsum H., Beresford S.A., and Vollset S.E. The controversy over homocysteine and cardiovascular risk. Am. J. Clin. Nutr. 72 (2000) 324-332
63. Verrotti A., Pascarella R., Trotta D., Giuva T., Morgese G., and Chiarelli F. Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine. Epilepsy Res. 41 (2000) 253-257
64. Verrotti A., Basciani F., Domizio S., Sabatino G., Morgese G., and Chiarelli F. Serum lipids and lipoproteins in patients treated with antiepileptic drugs. Pediatr. Neurol. 19 (1998) 364-367
65. Wald D.S., Law M., and Morris J.K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325 (2002) 1202
66. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
67. Yalcin E., Hassanzadeh A., and Mawlud K. The effects of long-term anticonvulsive treatment on serum lipid profile. Acta Paediatr. Jpn. 39 (1997) 342-345
68. Yoo J.H., and Hong S.B. A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants. Metabolism 48 (1999) 1047-1051